A Phase 4 interventional study of Symbicort® and Fasenra® in Asthma and Severe Eosinophilic Asthma, sponsored by AstraZeneca. Completed at 23 sites in 4 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-01-09.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.
Among the 39 studies testing benralizumab in Asthma, this one is the 15th largest by enrollment, is the only one that started in 2020, is one of 9 in phase 4, and was the 29th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
University of California, San Diego · Sites in United States
Ages 18–75
Endeavor Health · Sites in United States
Ages 18+
By country, each count listing its studies:
benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 170 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 128 across the 39 interventional studies. Of the 31 that completed or were terminated, 24 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 39 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 126th largest by enrollment of the 248 interventional ones that give a count, is one of 7 that started in 2020, is one of 23 in phase 4, and was the 261st registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing benralizumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
| NCT07654842Endeavor HealthFasenra: An Asthma Study | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies testing benralizumab in Asthma, from their registry updates:
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
This is a multicentre, randomised, open-label, parallel-group, active-controlled, phase IV study to assess the reduction of daily Symbicort® maintenance to anti-inflammatory reliever treatment only in participants with severe eosinophilic asthma on Fasenra® treatment, while maintaining asthma control.
This study will be conducted at 24 study sites in 3-5 countries. The study duration for each participant will be approximately 52-56 weeks. Approximately 240 participants with severe eosinophilic asthma taking high-dose Inhaled corticosteroids/ long-acting β2-agonist (ICS/LABA) who have been treated for severe eosinophilic asthma with at least 3 consecutive doses of Fasenra® and have clinically responded since the start of Fasenra® treatment (defined for the purpose of this study as an Asthma control questionnaire-5 item (ACQ-5 score) \<1.5 at Visit 1 and Visit 2b) will be enrolled into this open-label study. The study consists of a Screening Visit (Visit 1) and 4- to 8-week screening and run-in period (to align the randomisation study visit with the next Fasenra® injection), a reduction period of 32 weeks, and a 16-week maintenance period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
WOCBP must agree to use a highly effective method of (confirmed by the Investigator) from randomisation throughout the study duration and within 12 weeks after the last dose of study treatment. Highly effective forms of birth control (those that can achieve a failure rate of less than 1% per year when used consistently and correctly) include:
Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are . Women will be considered postmenopausal if they have been amenorrhoeic for ≥12 months prior to the planned date of randomisation without an alternative medical cause.
The following age-specific requirements apply:
For randomisation at Visit 2b, patients should fulfil the following criteria:
Exclusion Criteria:
Current , or history of malignancy, except for:
Prior/Concomitant Therapy
Concurrent participation in another clinical study with an Investigational Product or a post-authorisation safety study.
Other Exclusions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Benralizumab 30 mg every 8 weeks (Q8W) during the study period, and high-dose Symbicort maintenance 400/12 μg ×2 inhalations BID + Ventolin (salbutamol 100 μg) reliever as needed (PRN), tapering to, medium-dose Symbicort 200/6 μg ×2 inhalations BID maintenance + Symbicort 200/6 μg reliever PRN, low dose Symbicort 200/6 μg x 1 inhalation BID maintenance + Symbicort 200/6 μg reliever PRN; or Symbicort 200/6 μg reliever only, as per tapering scheme and depending on the degree of asthma control). The reduction period in this arm lasted for 32 weeks.
Drug: Symbicort® · Drug: Fasenra® · Drug: Ventolin®
Participants will receive Benralizumab 30 mg Q8W + high-dose Symbicort® 400/12 μg maintenance ×2 inhalations BID + Ventolin® (salbutamol 100 μg) reliever PRN therapy. Eligible participants randomised to the reference arm continued on high-dose Symbicort® maintenance treatment and Ventolin® reliever treatment.
Drug: Symbicort® · Drug: Fasenra® · Drug: Ventolin®
Participants will receive Budesonide 400 μg/formoterol fumarate 12 μg per inhalation or Budesonide 200 μg/formoterol fumarate 6 μg per inhalation.
Also known as: budesonide/formoterol
Participants will receive Benralizumab 30 mg/mL, 1 mL fill volume via subcutaneous injection every 4 weeks for first 3 doses (prior to study inclusion), every 8 weeks thereafter.
Also known as: benralizumab
Participants will receive Salbutamol sulfate 100 μg per inhalation as needed.
Also known as: salbutamol
Proportion of Patients Who Reduced Their Symbicort® Maintenance Dose at the End of the Reduction Period
Proportion of patients with non-missing Week 32 dose who reduced their Symbicort® maintenance dose at the end of the reduction period (Week 32) to: a) Medium-dose Symbicort® maintenance and reliever therapy (SMART), or b) Low-dose SMART, or c) Symbicort® anti-inflammatory reliever only.
Time frame: At Week 32
Change From Baseline in Asthma Control Questionnaire-5 Item (ACQ-5) Score at the End of the Reduction Period
Change from baseline in the ACQ-5 patient reported outcome. This instrument contains 5 asthma symptom questions, rated from 0 (total control) to 6 (severely uncontrolled). The ACQ-5 score is the mean of the responses. Mean scores ≤0.75 indicate well controlled, scores between \>0.75 and \<1.5 indicate partly controlled, ≥1.5 indicate not well controlled asthma, and individual changes of ≥0.5 are considered to be clinically meaningful. ACQ-5 deterioration is defined as at least a 0.5 unit increase in ACQ-5 score from baseline, and a decrease of at least 0.5 units from baseline indicates improved asthma control.
Time frame: Week 0 (baseline) and at Week 32
Change From Baseline in Standardised Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) at the End of the Reduction Period
The AQLQ(S)+12 is a Patient-Reported Outcome (PRO) that measures the health-related quality of life experienced by asthma patients. The questionnaire comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli). Patients are asked to recall their experiences during the previous 2 weeks before each visit and to score each of the questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). Range of Total Score = 0 - 7 as it is an average of responses to the individual questions. High score = better quality of life, and low score = poor quality of life. Change of \>0.5 from baseline is considered a meaningful improvement in score.
Time frame: Week 0 (baseline) and at Week 32
Number of Patients With no Deterioration in AQLQ(S)+12 at the End of the Reduction Period
The AQLQ(S)+12 is a PRO that measures the health-related quality of life experienced by asthma patients. The questionnaire comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli). Patients are asked to recall their experiences during the previous 2 weeks before each visit and to score each of the questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). AQLQ(S)+12 deterioration was defined as at least a 0.5 unit decrease in AQLQ(S)+12 total score from baseline. Patients with no deterioration include patients with improvement or no change.
Time frame: At Week 32
Number of Patients With no Deterioration in ACQ-5 at the End of the Reduction Period
Change from baseline in the ACQ-5 patient reported outcome. This instrument contains 5 asthma symptom questions, rated from 0 (total control) to 6 (severely uncontrolled). The ACQ-5 score is the mean of the responses. Mean scores ≤0.75 indicate well controlled, scores between \>0.75 and \<1.5 indicate partly controlled, ≥1.5 indicate not well controlled asthma, and individual changes of ≥0.5 are considered to be clinically meaningful. ACQ-5 deterioration is defined as at least a 0.5 units increase in ACQ-5 score from baseline, and a decrease of at least 0.5 units from baseline indicates improved asthma control.
Time frame: At Week 32
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) During the Study Period
The potential for benralizumab-treated patients to maintain lung function while stepping down Symbicort® maintenance treatment was assessed. The FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration, expressed in liters. Change from baseline pre-bronchodilator FEV1 calculated as post-baseline pre-bronchodilator FEV1 (L) minus baseline pre-bronchodilator FEV1 (L) for all post-baseline measurement points.
Time frame: At Week 0 (baseline), and at Weeks 8, 16, 24, 32, 40, and 48
Annualised Asthma Exacerbation Rate During the Study Period
Asthma exacerbation rate was assessed. An asthma exacerbation was defined as a worsening of asthma symptoms that led to any of the following: a) Temporary bolus/burst of systemic corticosteroids (≥3 consecutive days); b) Single depo-injectable dose of corticosteroids (equivalent to a 3-day bolus/burst); c) Visit to emergency room/urgent care (treatment \<24 hours) requiring systemic corticosteroids; d) Hospitalization (admission/evaluation ≥24 hours) due to asthma.
Time frame: From Week 0 up to Week 48
Cumulative Total Daily Inhaled Corticosteroids (ICS) Dose, by Period
The cumulative total daily ICS dose (maintenance +reliever) for: a) reduction period; b) maintenance period; c) study period was assessed.
Time frame: Reduction period (From Week 0 up to Week 32); maintenance period (From Week 32 up to Week 48); Study period (Week 0 up to end of maintenance period/ end of study)
Total Daily ICS Dose (Maintenance + Reliever) at the End of the Reduction Period
The mean total daily ICS dose (maintenance + reliever) during the 8 weeks prior to end of the reduction period was assessed.
Time frame: At Week 32
Proportion of Participants Using the Same Symbicort® Daily Dose at the End of the Maintenance Period (Week 48) That They Achieved at the End of the Reduction Period (Week 32)
Proportion of patients using the same Symbicort daily dose at the end of the maintenance period that they achieved at the end of the reduction period. Proportions were based on patients with non-missing Week 32 and Week 48 Symbicort doses.
Time frame: At Week 48
Number of Patients With at Least 1 Exacerbation Occurring From End of the Reduction Period to End of the Maintenance Period
Number of patients with at least 1 exacerbation occurring from end of the reduction period to end of the maintenance period.
Time frame: From Week 32 to Week 48
Total Daily ICS Dose From the End of the Reduction Period to the End of the Maintenance Period
Total daily ICS dose from the end of the reduction period to the end of the maintenance period.
Time frame: Week 32, Week 40, and Week 48
Change in ACQ-5 From the End of the Reduction Period to the End of the Maintenance Period
Change in ACQ-5 score from end of reduction to end of maintenance is reported. This instrument contains 5 asthma symptom questions, rated from 0 (total control) to 6 (severely uncontrolled). The ACQ-5 score is the mean of the responses. Mean scores ≤0.75 indicate well controlled, scores between \>0.75 and \<1.5 indicate partly controlled, ≥1.5 indicate not well controlled asthma, and individual changes of ≥0.5 are considered to be clinically meaningful. ACQ-5 deterioration is defined as at least a 0.5 unit increase in ACQ-5 score from baseline, and a decrease of at least 0.5 units from baseline indicates improved asthma control.
Time frame: From Week 32 to Week 48
Change in AQLQ(S)+12 From the End of the Reduction Period to the End of the Maintenance Period
Change in AQLQ(S)+12 from the end of the reduction period to the end of the maintenance period is reported. The AQLQ(S)+12 is a Patient-Reported Outcome (PRO) that measures the health-related quality of life experienced by asthma patients. The questionnaire comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli). Patients are asked to recall their experiences during the previous 2 weeks before each visit and to score each of the questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). Range of Total Score = 0 - 7 as it is an average of responses to the individual questions. High score = better quality of life, and low score = poor quality of life. Change of \>0.5 from baseline is considered a meaningful improvement in score.
Time frame: From Week 32 to Week 48
Change in FEV1 From the End of the Reduction Period to the End of the Maintenance Period
The change from the end of the reduction period to the end of the maintenance period for pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1) was calculated as Week 48 pre-bronchodilator FEV1 (Liter \[L\]) minus the maintenance period baseline pre-bronchodilator FEV1 (L). The FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration, expressed in liters.
Time frame: From Week 32 to Week 48
Number of Patients That Met Each Composite Endpoint Defining Clinical Remission
The number of patients meeting each individual component of the composite endpoint defining clinical remission (zero exacerbations, ACQ-5 \< 1.5, or ACQ-5 \<= 0.75, \< 10% FEV1 deterioration) at the end of reduction and maintenance periods were assessed.
Time frame: At Week 32 and Week 48
Number of Patients That Met 0, 1, 2, and All 3 Composite Remission Endpoints
Clinical remission in patients at end of the reduction and maintenance periods was assessed. A remission score, assigning 1 point for each clinical remission component achieved at week 32 or week 48,was calculated for patients who met 0, 1, 2, and all 3 remission criteria (zero exacerbations,ACQ-5 \< 1.5, or ACQ-5 \<= 0.75,\< 10% FEV1 deterioration). Total remission score ranges from 0 to 3. The higher the score, the more components of remission the patient achieved.
Time frame: At Week 32 and Week 48
Number of Patients With Adverse Events or Serious Adverse Events
The safety and tolerability of benralizumab in patients with severe asthma, while stepping down Symbicort® maintenance treatment and maintaining asthma symptom control was assessed.
Time frame: From Week 0 (randomization) to Week 48 or end of treatment (total period of study is 2.5 years)
The study was conducted between 27 July 2020 and 31 January 2023.
| Milestone | Treatment Reduction | Reference |
|---|---|---|
| Started | 125 | 43 |
| Completed | 117 | 37 |
| Not completed | 8 | 6 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Discontinued from study | 1 | 0 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Withdrawal by subject | 4 | 4 |
Proportion of patients with non-missing Week 32 dose who reduced their Symbicort® maintenance dose at the end of the reduction period (Week 32) to: a) Medium-dose Symbicort® maintenance and reliever therapy (SMART), or b) Low-dose SMART, or c) Symbicort® anti-inflammatory reliever only.
| Proportion of Participants | Treatment Reduction |
|---|---|
| Medium-dose SMART | 0.151 (0.0922 to 0.2285) |
| Low-dose SMART | 0.168 (0.1058 to 0.2476) |
| Symbicort® reliever-only dose | 0.605 (0.5113 to 0.6934) |
Change from baseline in the ACQ-5 patient reported outcome. This instrument contains 5 asthma symptom questions, rated from 0 (total control) to 6 (severely uncontrolled). The ACQ-5 score is the mean of the responses. Mean scores ≤0.75 indicate well controlled, scores between \>0.75 and \<1.5 indicate partly controlled, ≥1.5 indicate not well controlled asthma, and individual changes of ≥0.5 are considered to be clinically meaningful. ACQ-5 deterioration is defined as at least a 0.5 unit increase in ACQ-5 score from baseline, and a decrease of at least 0.5 units from baseline indicates improved asthma control.
| Score on a scale | Treatment Reduction | Reference |
|---|---|---|
| Change From Baseline in Asthma Control Questionnaire-5 Item (ACQ-5) Score at the End of the Reduction Period | 0.1617 ± 0.0393 | 0.0555 ± 0.0677 |
The AQLQ(S)+12 is a Patient-Reported Outcome (PRO) that measures the health-related quality of life experienced by asthma patients. The questionnaire comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli). Patients are asked to recall their experiences during the previous 2 weeks before each visit and to score each of the questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). Range of Total Score = 0 - 7 as it is an average of responses to the individual questions. High score = better quality of life, and low score = poor quality of life. Change of \>0.5 from baseline is considered a meaningful improvement in score.
| Score on a scale | Treatment Reduction | Reference |
|---|---|---|
| Change From Baseline in Standardised Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) at the End of the Reduction Period | -0.0279 ± 0.0559 | 0.0064 ± 0.0950 |
The AQLQ(S)+12 is a PRO that measures the health-related quality of life experienced by asthma patients. The questionnaire comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli). Patients are asked to recall their experiences during the previous 2 weeks before each visit and to score each of the questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). AQLQ(S)+12 deterioration was defined as at least a 0.5 unit decrease in AQLQ(S)+12 total score from baseline. Patients with no deterioration include patients with improvement or no change.
| Participants | Treatment Reduction | Reference |
|---|---|---|
| Improvement | 12 | 3 |
| No change | 73 | 28 |
Change from baseline in the ACQ-5 patient reported outcome. This instrument contains 5 asthma symptom questions, rated from 0 (total control) to 6 (severely uncontrolled). The ACQ-5 score is the mean of the responses. Mean scores ≤0.75 indicate well controlled, scores between \>0.75 and \<1.5 indicate partly controlled, ≥1.5 indicate not well controlled asthma, and individual changes of ≥0.5 are considered to be clinically meaningful. ACQ-5 deterioration is defined as at least a 0.5 units increase in ACQ-5 score from baseline, and a decrease of at least 0.5 units from baseline indicates improved asthma control.
| Participants | Treatment Reduction | Reference |
|---|---|---|
| Improvement | 6 | 2 |
| No change | 87 | 28 |
The potential for benralizumab-treated patients to maintain lung function while stepping down Symbicort® maintenance treatment was assessed. The FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration, expressed in liters. Change from baseline pre-bronchodilator FEV1 calculated as post-baseline pre-bronchodilator FEV1 (L) minus baseline pre-bronchodilator FEV1 (L) for all post-baseline measurement points.
| Liter | Treatment Reduction | Reference |
|---|---|---|
| Week 8 | 0.0411 ± 0.0183 | 0.0549 ± 0.0315 |
| Week 16 | 0.0299 ± 0.0215 | 0.0115 ± 0.0363 |
| Week 24 | -0.0536 ± 0.0317 | 0.0644 ± 0.0540 |
| Week 32 | -0.0824 ± 0.0285 | -0.0016 ± 0.0482 |
| Week 40 | -0.0953 ± 0.0280 | 0.0428 ± 0.0476 |
| Week 48 | -0.0889 ± 0.0272 | 0.0059 ± 0.0475 |
Asthma exacerbation rate was assessed. An asthma exacerbation was defined as a worsening of asthma symptoms that led to any of the following: a) Temporary bolus/burst of systemic corticosteroids (≥3 consecutive days); b) Single depo-injectable dose of corticosteroids (equivalent to a 3-day bolus/burst); c) Visit to emergency room/urgent care (treatment \<24 hours) requiring systemic corticosteroids; d) Hospitalization (admission/evaluation ≥24 hours) due to asthma.
| Events/Year | Treatment Reduction | Reference |
|---|---|---|
| Annualised Asthma Exacerbation Rate During the Study Period | 0.14 (0.09 to 0.23) | 0.14 (0.06 to 0.31) |
The cumulative total daily ICS dose (maintenance +reliever) for: a) reduction period; b) maintenance period; c) study period was assessed.
| Microgram | Treatment Reduction | Reference |
|---|---|---|
| Reduction period | 115956.8 ± 73223.93 | 312857.1 ± 81251.22 |
| Maintenance period | 50984.3 ± 51148.59 | 150400.0 ± 42180.46 |
| Study period | 157560.0 ± 114123.69 | 448933.3 ± 131247.22 |
The mean total daily ICS dose (maintenance + reliever) during the 8 weeks prior to end of the reduction period was assessed.
| Microgram | Treatment Reduction | Reference |
|---|---|---|
| Total Daily ICS Dose (Maintenance + Reliever) at the End of the Reduction Period | 380.028 ± 440.4995 | 1401.796 ± 316.9718 |
Proportion of patients using the same Symbicort daily dose at the end of the maintenance period that they achieved at the end of the reduction period. Proportions were based on patients with non-missing Week 32 and Week 48 Symbicort doses.
| Proportion | Treatment Reduction |
|---|---|
| Proportion of Participants Using the Same Symbicort® Daily Dose at the End of the Maintenance Period (Week 48) That They Achieved at the End of the Reduction Period (Week 32) | 0.958 (0.9039 to 0.9861) |
Number of patients with at least 1 exacerbation occurring from end of the reduction period to end of the maintenance period.
| Participants | Treatment Reduction | Reference |
|---|---|---|
| Number of Patients With at Least 1 Exacerbation Occurring From End of the Reduction Period to End of the Maintenance Period | 5 | 4 |
Total daily ICS dose from the end of the reduction period to the end of the maintenance period.
| Microgram | Treatment Reduction | Reference |
|---|---|---|
| Week 32 | 383.221 ± 440.9649 | 1438.685 ± 220.6355 |
| Week 40 | 408.458 ± 475.6986 | 1424.624 ± 321.5752 |
| Week 48 | 376.356 ± 449.6614 | 1265.356 ± 472.5244 |
Change in ACQ-5 score from end of reduction to end of maintenance is reported. This instrument contains 5 asthma symptom questions, rated from 0 (total control) to 6 (severely uncontrolled). The ACQ-5 score is the mean of the responses. Mean scores ≤0.75 indicate well controlled, scores between \>0.75 and \<1.5 indicate partly controlled, ≥1.5 indicate not well controlled asthma, and individual changes of ≥0.5 are considered to be clinically meaningful. ACQ-5 deterioration is defined as at least a 0.5 unit increase in ACQ-5 score from baseline, and a decrease of at least 0.5 units from baseline indicates improved asthma control.
| Score on a scale | Treatment Reduction | Reference |
|---|---|---|
| Change in ACQ-5 From the End of the Reduction Period to the End of the Maintenance Period | -0.07 ± 0.575 | -0.20 ± 0.814 |
Change in AQLQ(S)+12 from the end of the reduction period to the end of the maintenance period is reported. The AQLQ(S)+12 is a Patient-Reported Outcome (PRO) that measures the health-related quality of life experienced by asthma patients. The questionnaire comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli). Patients are asked to recall their experiences during the previous 2 weeks before each visit and to score each of the questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). Range of Total Score = 0 - 7 as it is an average of responses to the individual questions. High score = better quality of life, and low score = poor quality of life. Change of \>0.5 from baseline is considered a meaningful improvement in score.
| Score on a scale | Treatment Reduction | Reference |
|---|---|---|
| Change in AQLQ(S)+12 From the End of the Reduction Period to the End of the Maintenance Period | -0.008 ± 0.4720 | 0.060 ± 0.5658 |
The change from the end of the reduction period to the end of the maintenance period for pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1) was calculated as Week 48 pre-bronchodilator FEV1 (Liter \[L\]) minus the maintenance period baseline pre-bronchodilator FEV1 (L). The FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration, expressed in liters.
| Liter | Treatment Reduction | Reference |
|---|---|---|
| Change in FEV1 From the End of the Reduction Period to the End of the Maintenance Period | 0.0089 ± 0.2320 | 0.0040 ± 0.2264 |
The number of patients meeting each individual component of the composite endpoint defining clinical remission (zero exacerbations, ACQ-5 \< 1.5, or ACQ-5 \<= 0.75, \< 10% FEV1 deterioration) at the end of reduction and maintenance periods were assessed.
| Participants | Treatment Reduction | Reference |
|---|---|---|
| No asthma exacerbation at Week 32 | 108 | 37 |
| No asthma exacerbation at Week 48 | 101 | 32 |
| ACQ-5 <1.5 at Week 32 | 106 | 32 |
| ACQ-5 <1.5 at Week 48 | 103 | 32 |
| ACQ-5 ≤ 0.75 at Week 32 | 65 | 21 |
| ACQ-5 ≤ 0.75 at Week 48 | 68 | 21 |
| FEV1 < 10% decrease from baseline at Week 32 | 59 | 26 |
| FEV1 < 10% decrease from baseline at Week 48 | 66 | 23 |
Clinical remission in patients at end of the reduction and maintenance periods was assessed. A remission score, assigning 1 point for each clinical remission component achieved at week 32 or week 48,was calculated for patients who met 0, 1, 2, and all 3 remission criteria (zero exacerbations,ACQ-5 \< 1.5, or ACQ-5 \<= 0.75,\< 10% FEV1 deterioration). Total remission score ranges from 0 to 3. The higher the score, the more components of remission the patient achieved.
| Participants | Treatment Reduction | Reference |
|---|---|---|
| Remission score (Exacerbation, ACQ-5 ≤ 0.75, FEV1 < 10% decrease from baseline) at Week 32 — 0 | 2 | 0 |
| Remission score (Exacerbation, ACQ-5 ≤ 0.75, FEV1 < 10% decrease from baseline) at Week 32 — 1 | 15 | 5 |
| Remission score (Exacerbation, ACQ-5 ≤ 0.75, FEV1 < 10% decrease from baseline) at Week 32 — 2 | 40 | 8 |
| Remission score (Exacerbation, ACQ-5 ≤ 0.75, FEV1 < 10% decrease from baseline) at Week 32 — 3 | 29 | 15 |
| Remission score (Exacerbation, ACQ-5 ≤ 0.75, FEV1 < 10% decrease from baseline) at Week 48 — 0 | 1 | 1 |
| Remission score (Exacerbation, ACQ-5 ≤ 0.75, FEV1 < 10% decrease from baseline) at Week 48 — 1 | 15 | 4 |
| Remission score (Exacerbation, ACQ-5 ≤ 0.75, FEV1 < 10% decrease from baseline) at Week 48 — 2 | 41 | 9 |
| Remission score (Exacerbation, ACQ-5 ≤ 0.75, FEV1 < 10% decrease from baseline) at Week 48 — 3 | 32 | 14 |
| Remission score: Exacerbation, ACQ-5 < 1.5, FEV1 < 10% decrease from baseline at Week 32 — 0 | 1 | 0 |
| Remission score: Exacerbation, ACQ-5 < 1.5, FEV1 < 10% decrease from baseline at Week 32 — 1 | 5 | 2 |
| Remission score: Exacerbation, ACQ-5 < 1.5, FEV1 < 10% decrease from baseline at Week 32 — 2 | 32 | 5 |
| Remission score: Exacerbation, ACQ-5 < 1.5, FEV1 < 10% decrease from baseline at Week 32 — 3 | 48 | 21 |
| Remission score: Exacerbation, ACQ-5 < 1.5, FEV1 < 10% decrease from baseline at Week 48 — 0 | 0 | 0 |
| Remission score: Exacerbation, ACQ-5 < 1.5, FEV1 < 10% decrease from baseline at Week 48 — 1 | 5 | 2 |
| Remission score: Exacerbation, ACQ-5 < 1.5, FEV1 < 10% decrease from baseline at Week 48 — 2 | 36 | 7 |
| Remission score: Exacerbation, ACQ-5 < 1.5, FEV1 < 10% decrease from baseline at Week 48 — 3 | 48 | 19 |
The safety and tolerability of benralizumab in patients with severe asthma, while stepping down Symbicort® maintenance treatment and maintaining asthma symptom control was assessed.
| Participants | Treatment Reduction | Reference |
|---|---|---|
| Any adverse event (AE) | 91 | 35 |
| Any AE with outcome = death | 0 | 0 |
| Any serious adverse event (including events with outcome = death) | 12 | 5 |
| Any AE leading to discontinuation of benralizumab | 3 | 1 |
| Any AE leading to discontinuation of Symbicort | 3 | 1 |
| Any AE leading to discontinuation of Ventolin | 2 | 1 |
| Any AE leading to withdrawal from study | 3 | 1 |
Collected over Run-In period: Week -8 to -4 to Week 0 before randomization (total period of 8 weeks); Treatment Period (Treatment reduction and reference): From Week 0 (Randomization) to Week 48 or end of treatment (total period of study is 2.5 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Run-In Period | 0/167 (0%) | 1/167 (0.6%) | 5/167 (3%) |
| Treatment Reduction | 0/125 (0%) | 12/125 (9.6%) | 46/125 (36.8%) |
| Reference | 0/42 (0%) | 5/42 (11.9%) | 20/42 (47.6%) |
| Event | Run-In Period | Treatment Reduction | Reference |
|---|---|---|---|
| Helicobacter infectionInfections and infestations | 0/167 | 0/125 | 1/42 |
| Atrial flutterCardiac disorders | 0/167 | 0/125 | 1/42 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/167 | 0/125 | 1/42 |
| Inguinal herniaGastrointestinal disorders | 0/167 | 0/125 | 1/42 |
| Vaccination complicationInjury, poisoning and procedural complications | 0/167 | 0/125 | 1/42 |
| InfluenzaInfections and infestations | 0/167 | 1/125 | 0/42 |
| Lower respiratory tract infectionInfections and infestations | 0/167 | 1/125 | 0/42 |
| OrchitisInfections and infestations | 0/167 | 1/125 | 0/42 |
| Periorbital abscessInfections and infestations | 0/167 | 1/125 | 0/42 |
| Gallbladder adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/167 | 1/125 | 0/42 |
| Event | Run-In Period | Treatment Reduction | Reference |
|---|---|---|---|
| COVID-19Infections and infestations | 2/167 | 19/125 | 9/42 |
| NasopharyngitisInfections and infestations | 3/167 | 10/125 | 7/42 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/167 | 17/125 | 4/42 |
| RhinitisInfections and infestations | 0/167 | 1/125 | 3/42 |
| BronchitisInfections and infestations | 0/167 | 7/125 | 1/42 |
The Full Analysis Set (FAS) included all randomised patients, irrespective of their protocol adherence and continued participation in the study.
| Age, Continuous(Years) | Treatment Reduction | Reference | Total |
|---|---|---|---|
| Mean | 58.1 ± 12.44 | 56.5 ± 11.70 | 57.7 ± 12.24 |
| Sex: Female, Male(Participants) | Treatment Reduction | Reference | Total |
|---|---|---|---|
| Female | 69 | 20 | 89 |
| Male | 56 | 23 | 79 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Reduction | Reference | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 6 | 14 |
| Not Hispanic or Latino | 91 | 28 | 119 |
| Unknown or Not Reported | 26 | 9 | 35 |
| Race/Ethnicity, Customized(Participants) | Treatment Reduction | Reference | Total |
|---|---|---|---|
| White | 95 | 31 | 126 |
| Asian | 0 | 2 | 2 |
| Other | 2 | 1 | 3 |
| Not Reported | 5 | 0 | 5 |
| Missing | 23 | 9 | 32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jul 2020 to primary completion in Jan 2023, 30 months.
Results were first posted in Jan 2025, 1 year 11 months after primary completion.
Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 30 months is above that.
Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab